PharmaBlock Sciences Nanjing Inc
SZSE:300725
PharmaBlock Sciences Nanjing Inc
Revenue
PharmaBlock Sciences Nanjing Inc
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
PharmaBlock Sciences Nanjing Inc
SZSE:300725
|
Revenue
¥1.6B
|
CAGR 3-Years
9%
|
CAGR 5-Years
21%
|
CAGR 10-Years
N/A
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Revenue
¥12.3B
|
CAGR 3-Years
7%
|
CAGR 5-Years
7%
|
CAGR 10-Years
N/A
|
|
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
|
Revenue
¥10.9B
|
CAGR 3-Years
13%
|
CAGR 5-Years
15%
|
CAGR 10-Years
23%
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Revenue
¥28B
|
CAGR 3-Years
3%
|
CAGR 5-Years
4%
|
CAGR 10-Years
14%
|
|
|
C
|
CSPC Innovation Pharmaceutical Co Ltd
SZSE:300765
|
Revenue
¥2B
|
CAGR 3-Years
11%
|
CAGR 5-Years
10%
|
CAGR 10-Years
N/A
|
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Revenue
¥5.8B
|
CAGR 3-Years
94%
|
CAGR 5-Years
37%
|
CAGR 10-Years
N/A
|
|
PharmaBlock Sciences Nanjing Inc
Glance View
PharmaBlock Sciences (Nanjing), Inc. engages in the innovation of chemistry products and services throughout the pharmaceutical research and development process. The company is headquartered in Nanjing, Jiangsu and currently employs 1,735 full-time employees. The company went IPO on 2017-11-10. The firm's primary products include aromatic heterocyclic drug molecular building blocks, common saturated alicyclic drug molecular building blocks, four-membered ring drug molecular building blocks and special saturated ring drug molecular building blocks. The firm is also involved in development, production and sales of pharmaceutical intermediates, and provides technical services related to the development and process production of pharmaceutical molecular building blocks.
See Also
What is PharmaBlock Sciences Nanjing Inc's Revenue?
Revenue
1.6B
CNY
Based on the financial report for Sep 30, 2024, PharmaBlock Sciences Nanjing Inc's Revenue amounts to 1.6B CNY.
What is PharmaBlock Sciences Nanjing Inc's Revenue growth rate?
Revenue CAGR 5Y
21%
Over the last year, the Revenue growth was -8%. The average annual Revenue growth rates for PharmaBlock Sciences Nanjing Inc have been 9% over the past three years , 21% over the past five years .
You don't have any saved screeners yet